T1	tradename 125 134	Marqibo (
T3	activeingredient 134 162	vinCRIStine sulfate LIPOSOME
T5	nanoparticle 163 172	injection
T7	tradename 235 244	Marqibo (
T9	activeingredient 244 272	vinCRIStine sulfate LIPOSOME
T11	nanoparticle 273 282	injection
T13	tradename 286 293	Marqibo
T15	activeingredient 295 323	vinCRIStine sulfate LIPOSOME
T17	nanoparticle 324 333	injection
T19	routeofadministration 339 359	intravenous infusion
T21	fdaapprovaldate 383 387	2012
T23	routeofadministration 464 479	Intravenous Use
T25	tradename 584 593	Marqibo (
T27	activeingredient 593 621	vinCRIStine sulfate LIPOSOME
T29	nanoparticle 622 631	injection
T31	activeingredient 675 704	vinCRIStine sulfate injection
T33	tradename 818 828	Marqibo is
T35	chemoclass 831 855	vinca alkaloid indicated
T37	indication 897 972	Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)in
T39	routeofadministration 1250 1265	Intravenous use
T41	tradename 1326 1336	Marqibo at
T43	dose 1347 1371	2.25 mg/m2 intravenously
T45	routeofadministration 1372 1376	over
T47	frequency 1384 1403	once every 7 days (
T49	tradename 1510 1521	Marqibo Kit
T51	tradename 1566 1575	Marqibo (
T53	activeingredient 1575 1594	vinCRIStine sulfate
T55	nanoparticle 1595 1613	LIPOSOME injection
T57	activeingredient 1648 1669	vincristine sulfate (
T59	tradename 1700 1710	Marqibo is
T61	tradename 1815 1825	Marqibo is
T63	activeingredient 1879 1901	vincristine sulfate or
T65	tradename 1933 1942	Marqibo (
T67	activeingredient 1942 1961	vinCRIStine sulfate
T69	nanoparticle 1962 1980	LIPOSOME injection
T71	tradename 1988 1998	Marqibo is
T73	tradename 2381 2393	Marqibo only
T75	tradename 2505 2513	Marqibo.
T77	tradename 2577 2589	Marqibo dose
T79	adversereaction 3243 3255	constipation
T81	adversereaction 3257 3263	nausea
T83	adversereaction 3265 3272	pyrexia
T85	adversereaction 3274 3281	fatigue
T87	adversereaction 3283 3304	peripheral neuropathy
T89	adversereaction 3306 3325	febrile neutropenia
T91	adversereaction 3327 3335	diarrhea
T93	adversereaction 3337 3343	anemia
T95	adversereaction 3345 3363	decreased appetite
T97	adversereaction 3369 3379	insomnia (
T99	company 3432 3453	Talon Therapeutics at
T101	tradename 3540 3550	Marqibo is
T103	activeingredient 3620 3641	vincristine sulfate (
T105	tradename 3725 3735	Marqibo in
T107	routeofadministration 3891 3906	INTRAVENOUS USE
T109	indication 3946 3958	Aduld ALL in
T111	routeofadministration 4218 4233	Intravenous Use
T113	adversereaction 4246 4273	Extravasation Tissue Injury
T115	adversereaction 4276 4277	5
T117	adversereaction 4281 4300	Neurologic Toxicity
T119	adversereaction 4303 4304	5
T121	adversereaction 4308 4324	Myelosuppression
T123	adversereaction 4331 4351	Tumor Lysis Syndrome
T125	adversereaction 4354 4355	5
T127	adversereaction 4359 4393	Constipation and Bowel Obstruction
T129	adversereaction 4395 4396	5
T131	adversereaction 4400 4407	Fatigue
T133	adversereaction 4409 4410	5
T135	adversereaction 4414 4430	Hepatic Toxicity
T137	adversereaction 4432 4433	5
T139	adversereaction 4437 4457	Embryofetal Toxicity
T141	indication 5247 5275	Acute Lymphoblastic Leukemia
T143	routeofadministration 5322 5337	Intravenous Use
T145	routeofadministration 5440 5466	intrathecal administration
T147	tradename 5469 5478	Marqibo (
T149	activeingredient 5478 5506	vinCRIStine sulfate LIPOSOME
T151	nanoparticle 5507 5516	injection
T153	activeingredient 5560 5589	vinCRIStine sulfate injection
T155	indication 5715 5727	Adult ALL in
T157	tradename 5756 5763	Marqibo
T159	indication 5818 5894	Philadelphia chromosome negative (Ph ) acute lymphoblastic leukemia (ALL) in
T161	routeofadministration 6173 6188	Intravenous Use
T163	tradename 6231 6240	Marqibo (
T165	activeingredient 6240 6268	vinCRIStine sulfate LIPOSOME
T167	nanoparticle 6269 6278	injection
T169	activeingredient 6322 6351	vincristine sulfate injection
T171	tradename 6497 6507	Marqibo is
T173	dose 6508 6532	2.25 mg/m2 intravenously
T175	routeofadministration 6533 6537	over
T177	frequency 6545 6563	once every 7 days.
T179	tradename 6566 6576	Marqibo is
T181	nanoparticle 6577 6598	liposome encapsulated
T183	activeingredient 6599 6611	vincristine.
T185	tradename 6666 6676	Marqibo is
T187	tradename 6873 6885	Marqibo only
T189	tradename 7124 7139	Marqibo related
T191	tradename 7318 7326	Marqibo.
T193	tradename 7501 7509	Marqibo.
T195	tradename 7621 7633	Marqibo dose
T197	dose 7637 7645	2 mg/m2.
T199	tradename 7706 7717	Marqibo for
T201	dose 7836 7844	2 mg/m2:
T203	tradename 7864 7872	Marqibo.
T205	tradename 7933 7945	Marqibo dose
T207	dose 7949 7961	1.825 mg/m2.
T209	tradename 8024 8035	Marqibo for
T211	dose 8153 8165	1.825 mg/m2:
T213	tradename 8185 8193	Marqibo.
T215	tradename 8246 8258	Marqibo dose
T217	dose 8262 8272	1.5 mg/m2.
T219	tradename 8739 8746	Marqibo
T221	tradename 8749 8760	Marqibo Kit
T223	tradename 9171 9182	Marqibo and
T225	tradename 9256 9263	Marqibo
T227	activeingredient 9265 9284	vinCRIStine sulfate
T229	nanoparticle 9285 9293	LIPOSOME
T231	tradename 9503 9511	Marqibo.
T233	tradename 9514 9527	Marqibo takes
T235	tradename 9637 9648	Marqibo due
T237	tradename 9834 9842	Marqibo.
T239	tradename 9870 9882	Marqibo that
T241	nanoparticle 9956 9974	Liposome Injection
T243	activeingredient 9980 10009	VinCRIStine Sulfate Injection
T245	tradename 10927 10938	Marqibo Kit
T247	nanoparticle 11472 11490	Liposome Injection
T249	activeingredient 11495 11524	VinCRIStine Sulfate Injection
T251	nanoparticle 11575 11593	Liposome Injection
T253	nanoparticle 11641 11659	Liposome Injection
T255	inactiveingredient 11669 11695	Sodium Phosphate Injection
T257	activeingredient 11723 11752	VinCRIStine Sulfate Injection
T259	activeingredient 11774 11803	VinCRIStine Sulfate Injection
T261	inactiveingredient 11813 11839	Sodium Phosphate Injection
T263	inactiveingredient 11899 11925	Sodium Phosphate Injection
T265	inactiveingredient 12011 12037	Sodium Phosphate Injection
T267	inactiveingredient 12161 12187	Sodium Phosphate Injection
T269	activeingredient 12204 12233	VinCRIStine Sulfate Injection
T271	nanoparticle 12261 12279	Liposome Injection
T273	inactiveingredient 12285 12311	Sodium Phosphate Injection
T275	inactiveingredient 12548 12574	Sodium Phosphate Injection
T277	tradename 12666 12683	Marqibo Overlabel
T279	tradename 12975 12992	Marqibo Overlabel
T281	inactiveingredient 13023 13049	Sodium Phosphate Injection
T283	tradename 13087 13094	Marqibo
T285	activeingredient 13097 13125	vinCRIStine sulfate LIPOSOME
T287	nanoparticle 13126 13135	injection
T289	tradename 13344 13353	Marqibo (
T291	activeingredient 13353 13381	vinCRIStine sulfate LIPOSOME
T293	nanoparticle 13382 13391	injection
T295	activeingredient 13426 13446	vincristine sulfate.
T297	tradename 13599 13611	Marqibo with
T299	tradename 13725 13737	Marqibo dose
T301	tradename 13845 13857	Marqibo dose
T303	tradename 13982 13994	Marqibo into
T305	tradename 14236 14255	Marqibo preparation
T307	activeingredient 14424 14448	vincristine sulfate into
T309	nanoparticle 14453 14463	liposomes.
T311	tradename 14906 14916	Marqibo is
T313	tradename 14953 14964	Marqibo Kit
T315	tradename 15055 15064	Marqibo (
T317	activeingredient 15064 15092	vinCRIStine sulfate LIPOSOME
T319	nanoparticle 15093 15102	injection
T321	activeingredient 15137 15157	vincristine sulfate.
T323	tradename 15184 15194	Marqibo is
T325	tradename 15294 15304	Marqibo is
T327	activeingredient 15358 15380	vincristine sulfate or
T329	tradename 15412 15421	Marqibo (
T331	activeingredient 15421 15449	vinCRIStine sulfate LIPOSOME
T333	nanoparticle 15450 15459	injection
T335	tradename 15464 15474	Marqibo is
T337	routeofadministration 15564 15579	Intravenous Use
T339	tradename 16349 16359	Marqibo is
T341	indication 16543 16561	adult ALL patients
T343	tradename 16699 16708	Marqibo [
T345	adversereaction 16754 16770	Myelosuppression
T347	adversereaction 16772 16779	Monitor
T349	tradename 16824 16832	Marqibo.
T351	adversereaction 16851 16862	neutropenia
T353	adversereaction 16864 16880	thrombocytopenia
T355	adversereaction 16885 16900	anemia develops
T357	tradename 16911 16923	Marqibo dose
T359	adversereaction 16995 17015	Tumor Lysis Syndrome
T361	adversereaction 17018 17048	Tumor lysis syndrome (TLS) may
T363	indication 17072 17085	ALL receiving
T365	tradename 17086 17105	Marqibo. Anticipate
T367	adversereaction 17141 17175	Constipation and Bowel Obstruction
T369	adversereaction 17178 17183	Ileus
T371	adversereaction 17185 17202	bowel obstruction
T373	adversereaction 17208 17239	colonic pseudo obstruction have
T375	tradename 17252 17263	Marqibo can
T377	adversereaction 17270 17284	constipation [
T379	adversereaction 17375 17387	constipation
T381	adversereaction 17389 17406	bowel obstruction
T383	adversereaction 17415 17430	paralytic ileus
T385	adversereaction 17671 17686	Fatigue Marqibo
T387	tradename 17687 17690	can
T389	adversereaction 17704 17712	fatigue.
T391	tradename 17713 17725	Marqibo dose
T393	adversereaction 17790 17806	Hepatic Toxicity
T395	adversereaction 17809 17884	Fatal liver toxicity and elevated levels of aspartate aminotransferase have
T397	adversereaction 17894 17942	Elevated levels of aspartate aminotransferase of
T399	tradename 18058 18069	Marqibo for
T401	adversereaction 18070 18087	hepatic toxicity.
T403	adversereaction 18097 18125	Embryofetal Toxicity Marqibo
T405	tradename 18126 18129	can
T407	activeingredient 18186 18214	Vincristine sulfate liposome
T409	nanoparticle 18215 18224	injection
T411	tradename 18372 18380	Marqibo.
T413	tradename 18436 18446	Marqibo in
T415	tradename 18539 18555	Marqibo clinical
T417	routeofadministration 18899 18914	intravenous use
T419	adversereaction 18960 18989	Extravasation tissue injury [
T421	adversereaction 19027 19050	Peripheral Neuropathy [
T423	adversereaction 19087 19105	Myelosuppression [
T425	adversereaction 19143 19164	Tumor lysis syndrome[
T427	adversereaction 19201 19237	Constipation and bowel obstruction [
T429	adversereaction 19274 19283	Fatigue [
T431	adversereaction 19320 19338	Hepatic toxicity [
T433	indication 19754 19792	Ph- Adult Acute Lymphoblastic Leukemia
T435	tradename 19795 19802	Marqibo
T437	dose 19817 19827	2.25 mg/m2
T439	frequency 19828 19834	weekly
T441	adversereaction 20014 20028	constipation (
T443	adversereaction 20034 20042	nausea (
T445	adversereaction 20048 20057	pyrexia (
T447	adversereaction 20063 20072	fatigue (
T449	adversereaction 20078 20101	peripheral neuropathy (
T451	adversereaction 20107 20128	febrile neutropenia (
T453	adversereaction 20134 20144	diarrhea (
T455	adversereaction 20150 20158	anemia (
T457	adversereaction 20164 20184	decreased appetite (
T459	adversereaction 20194 20204	insomnia (
T461	adversereaction 20636 20655	Febrile Neutropenia
T463	adversereaction 20667 20678	Neutropenia
T465	adversereaction 20690 20696	Anemia
T467	adversereaction 20708 20724	Thrombocytopenia
T469	adversereaction 20760 20769	Pneumonia
T471	adversereaction 20779 20791	Septic Shock
T473	adversereaction 20801 20826	Staphylococcal Bacteremia
T475	adversereaction 20861 20900	Peripheral Sensory and Motor Neuropathy
T477	adversereaction 20913 20925	Constipation
T479	adversereaction 20936 20941	Ileus
T481	adversereaction 20943 20969	Colonic Pseudo Obstruction
T483	adversereaction 20980 20988	Asthenia
T485	adversereaction 21000 21017	Muscular Weakness
T487	adversereaction 21087 21107	Respiratory Distress
T489	adversereaction 21118 21137	Respiratory Failure
T491	adversereaction 21212 21219	Pyrexia
T493	adversereaction 21231 21238	Fatigue
T495	adversereaction 21250 21254	Pain
T497	adversereaction 21304 21318	Abdominal Pain
T499	adversereaction 21356 21392	Aspartate Aminotransferase Increased
T501	adversereaction 21432 21443	Hypotension
T503	adversereaction 21488 21509	Mental Status Changes
T505	adversereaction 21549 21563	Cardiac Arrest
T507	adversereaction 21959 21980	febrile neutropenia (
T509	adversereaction 21988 21997	pyrexia (
T511	adversereaction 22005 22018	hypotension (
T513	adversereaction 22025 22047	respiratory distress (
T515	adversereaction 22058 22074	cardiac arrest (
T517	adversereaction 22350 22373	peripheral neuropathy (
T519	adversereaction 22406 22428	tumor lysis syndrome (
T521	adversereaction 22522 22547	decreased vibratory sense
T523	adversereaction 22549 22561	facial palsy
T525	adversereaction 22563 22575	hyporeflexia
T527	adversereaction 22577 22589	constipation
T529	adversereaction 22591 22599	asthenia
T531	adversereaction 22601 22608	fatigue
T533	adversereaction 22614 22634	musculoskeletal pain
T535	tradename 23069 23087	Marqibo.Marqibo is
T537	activeingredient 23157 23177	vincristine sulfate.
T539	routeofadministration 23193 23227	oral or intravenous administration
T541	co-administereddrug 23231 23285	phenytoin and antineoplastic chemotherapy combinations
T543	activeingredient 23314 23338	vincristine sulfate have
T545	activeingredient 23452 23471	Vincristine sulfate
T547	tradename 23493 23500	Marqibo
T549	activeingredient 24040 24059	Vincristine sulfate
T551	tradename 24081 24088	Marqibo
T553	tradename 24317 24334	Marqibo Therefore
T555	tradename 24594 24605	Marqibo can
T557	activeingredient 24898 24917	vincristine sulfate
T559	nanoparticle 24918 24936	liposome injection
T561	routeofadministration 24937 24957	intravenously during
T563	activeingredient 24989 25014	vincristine sulfate doses
T565	dose 25018 25037	0.022 to 0.09 mg/kg
T567	frequency 25037 25042	/day.
T569	dose 25304 25315	0.044 mg/kg
T571	frequency 25315 25322	/day in
T573	tradename 25844 25854	Marqibo in
T575	tradename 26316 26327	Marqibo has
T577	activeingredient 26391 26413	vincristine sulfate is
T579	tradename 26520 26531	Marqibo has
T581	tradename 26578 26589	Marqibo was
T583	tradename 26810 26820	Marqibo in
T585	tradename 26987 26996	Marqibo (
T587	activeingredient 26996 27015	vinCRIStine sulfate
T589	nanoparticle 27016 27034	LIPOSOME injection
T591	dose 27066 27075	2.4 mg/m2
T593	adversereaction 27105 27124	motor neuropathy of
T595	adversereaction 27134 27154	grand mal seizure of
T597	adversereaction 27168 27229	elevated aspartate aminotransferase and hyperbilirubinemia of
T599	tradename 27337 27346	Marqibo (
T601	activeingredient 27346 27365	vinCRIStine sulfate
T603	nanoparticle 27366 27384	LIPOSOME injection
T605	activeingredient 27389 27413	vincristine encapsulated
T607	corecomposition 27417 27452	sphingomyelin/cholesterol liposomes
T609	nanoparticle 27453 27456	for
T611	routeofadministration 27457 27483	intravenous administration
T613	tradename 27512 27522	Marqibo is
T615	activeingredient 27523 27543	vincristine sulfate.
T617	activeingredient 27546 27568	Vincristine sulfate is
T619	chemoclass 27571 27594	vinca alkaloid isolated
T621	molecularweight 27794 27802	923.04 (
T623	molecularweight 27815 27823	824.98 (
T625	activeingredient 27905 27927	vincristine sulfate is
T627	activeingredient 28000 28014	Vincristine is
T629	corecomposition 28033 28058	Sphingomyelin/Cholesterol
T631	nanoparticle 28059 28068	liposome.
T633	nanoparticle 28096 28108	liposome are
T635	corecomposition 28109 28141	sphingomyelin and cholesterol at
T637	tradename 28224 28240	Marqibo contains
T639	activeingredient 28246 28265	vincristine sulfate
T641	inactiveingredient 28274 28282	mannitol
T643	corecomposition 28292 28305	sphingomyelin
T645	corecomposition 28315 28326	cholesterol
T647	inactiveingredient 28334 28348	sodium citrate
T649	inactiveingredient 28356 28367	citric acid
T651	inactiveingredient 28376 28392	sodium phosphate
T653	inactiveingredient 28405 28421	sodium chloride.
T655	tradename 28426 28435	Marqibo (
T657	activeingredient 28435 28454	vinCRIStine sulfate
T659	nanoparticle 28455 28473	LIPOSOME injection
T661	corecomposition 28604 28629	sphingomyelin/cholesterol
T663	nanoparticle 28631 28640	liposomes
T665	nanoparticle 28662 28675	liposome mean
T667	particlediameter 28688 28695	100 nm.
T669	nanoparticle 28750 28760	liposomes.
T671	tradename 28767 28778	Marqibo Kit
T673	tradename 28818 28827	Marqibo (
T675	activeingredient 28827 28846	vinCRIStine sulfate
T677	nanoparticle 28847 28865	LIPOSOME injection
T679	activeingredient 28877 28906	VinCRIStine Sulfate Injection
T681	activeingredient 28932 28961	VinCRIStine Sulfate Injection
T683	activeingredient 28989 29010	vincristine sulfate (
T685	activeingredient 29045 29061	vincristine free
T687	inactiveingredient 29084 29093	mannitol.
T689	corecomposition 29095 29120	Sphingomyelin/Cholesterol
T691	nanoparticle 29121 29139	Liposome Injection
T693	corecomposition 29160 29185	Sphingomyelin/Cholesterol
T695	nanoparticle 29186 29204	Liposome Injection
T697	corecomposition 29233 29246	sphingomyelin
T699	corecomposition 29259 29270	cholesterol
T701	inactiveingredient 29283 29294	citric acid
T703	inactiveingredient 29307 29321	sodium citrate
T705	inactiveingredient 29356 29382	Sodium Phosphate Injection
T707	inactiveingredient 29406 29432	Sodium Phosphate Injection
T709	inactiveingredient 29463 29491	dibasic sodium phosphate and
T711	inactiveingredient 29505 29521	sodium chloride.
T713	tradename 29581 29591	Marqibo is
T715	corecomposition 29594 29619	sphingomyelin/cholesterol
T717	nanoparticle 29620 29641	liposome encapsulated
T719	activeingredient 29657 29677	vincristine sulfate.
T721	activeingredient 29691 29716	vincristine sulfate binds
T723	activeingredient 29848 29878	vincristine sulfate stabilizes
T725	tradename 30052 30063	Marqibo was
T727	indication 30112 30119	ALL who
T729	tradename 30131 30143	Marqibo dose
T731	dose 30147 30170	2.25 mg/m2 administered
T733	routeofadministration 30183 30203	intravenous infusion
T735	activeingredient 30266 30289	vincristine sulfate are
T737	activeingredient 30315 30341	vincristine sulfate levels
T739	nanoparticle 30370 30391	liposome encapsulated
T741	activeingredient 30493 30518	vincristine sulfate after
T743	activeingredient 30551 30570	vincristine sulfate
T745	indication 30667 30703	Acute Lymphoblastic Leukemia Treated
T747	dose 30709 30719	2.25 mg/m2
T749	tradename 30720 30728	Marqiboa
T751	auc 30778 30783	14566
T753	auc 30798 30829	7036 26074 ( &#x20ac; ng/mL) CL
T755	clearance 30835 30838	345
T757	clearance 30849 30868	148 783 (mL/h) Cmax
T759	cmax 30874 30878	1220
T761	cmax 30889 30907	919 1720 (ng/mL) a
T763	tradename 30985 30995	Marqibo is
T765	clearance 31002 31010	345 mL/h
T767	dose 31025 31036	2.25 mg/m2.
T769	activeingredient 31102 31125	vincristine s ulfate at
T771	clearance 31126 31143	189 mL/min/m2 (11
T773	clearance 31144 31153	340 mL/h)
T775	tradename 31179 31198	Marqibo contributes
T777	tradename 31224 31240	Marqibo relative
T779	activeingredient 31258 31278	vincristine sulfate.
T781	routeofadministration 31290 31316	intravenous administration
T783	tradename 31320 31327	Marqibo
T785	activeingredient 31384 31407	vincristine sulfate and
T787	tradename 31459 31471	Marqibo dose
T789	activeingredient 31590 31610	vincristine sulfate.
T791	activeingredient 31637 31665	vincristine sulfate infusion
T793	activeingredient 31685 31714	vincristine sulfate excretion
T795	tradename 31941 31951	Marqibo or
T797	activeingredient 31966 31986	vincristine sulfate.
T799	activeingredient 32100 32119	vincristine sulfate
T801	tradename 32121 32132	Marqibo may
T803	tradename 32201 32209	Marqibo.
T805	activeingredient 32223 32238	vincristine was
T807	tradename 32362 32373	Marqibo can
T809	activeingredient 32445 32479	vincristine sulfate Administration
T811	activeingredient 32483 32494	vincristine
T813	nanoparticle 32495 32513	liposome injection
T815	activeingredient 32740 32760	vincristine sulfate.
T817	activeingredient 33019 33038	vincristine sulfate
T819	nanoparticle 33039 33057	liposome injection
T821	activeingredient 33075 33098	vincristine sulfate was
T823	routeofadministration 33123 33141	intravenously once
T825	frequency 33142 33163	per week for 6 weeks.
T827	activeingredient 33241 33260	vincristine sulfate
T829	nanoparticle 33261 33279	liposome injection
T831	activeingredient 33304 33326	vincristine sulfate at
T833	activeingredient 33333 33358	vincristine sulfate doses
T835	dose 33362 33368	2mg/m2
T837	frequency 33368 33377	/week and
T839	activeingredient 33624 33643	vincristine sulfate
T841	nanoparticle 33644 33662	liposome injection
T843	activeingredient 33806 33826	vincristine sulfate.
T845	dose 33896 33906	2 mg/m2 of
T847	routeofadministration 33907 33928	intravenous liposomal
T849	nanoparticle 33929 33931	or
T851	activeingredient 33946 33972	vincristine sulfate showed
T853	activeingredient 33997 34019	vincristine sulfate in
T855	activeingredient 34125 34144	vincristine sulfate
T857	nanoparticle 34145 34163	liposome injection
T859	indication 34198 34226	Acute Lymphoblastic Leukemia
T861	tradename 34228 34239	Marqibo was
T863	indication 34375 34414	Philadelphia chromosome negative ALL in
T865	routeofadministration 34858 34878	intravenous Marqibo
T867	tradename 34879 34890	monotherapy
T869	dose 34894 34909	2.25 mg/m2 over
T871	frequency 34921 34934	every 7 days.
T873	tradename 35076 35084	Marqibo.
T875	activeingredient 35134 35157	vincristine sulfate and
T877	indication 35515 35522	ALL and
T879	indication 35544 35548	ALL.
T881	tradename 37197 37208	Marqibo Kit
T883	activeingredient 37258 37287	VinCRIStine Sulfate Injection
T885	nanoparticle 37395 37413	Liposome Injection
T887	inactiveingredient 37479 37505	Sodium Phosphate Injection
T889	inactiveingredient 37601 37627	Sodium Phosphate Injection
T891	tradename 37656 37665	Marqibo (
T893	activeingredient 37665 37684	vinCRIStine sulfate
T895	nanoparticle 37685 37703	LIPOSOME injection
T897	tradename 37778 37789	Marqibo Kit
T899	tradename 37987 37995	Marqibo:
T901	adversereaction 37998 38026	Extravasation Tissue Injury:
T903	tradename 38243 38254	Marqibo may
T905	adversereaction 38261 38272	fatigue and
T907	adversereaction 38285 38307	peripheral neuropathy.
T909	adversereaction 38445 38475	Gastrointestinal/Constipation:
T911	tradename 38495 38506	Marqibo may
T913	adversereaction 38518 38531	constipation.
T915	adversereaction 38563 38578	constipation by
T917	adversereaction 38780 38824	constipation such bowel movement infrequency
T919	adversereaction 38826 38840	abdominal pain
T921	adversereaction 38842 38850	bloating
T923	adversereaction 38852 38860	diarrhea
T925	adversereaction 38862 38868	nausea
T927	adversereaction 38873 38883	vomiting [
T929	tradename 39039 39048	Marqibo [
T931	tradename 39207 39220	Marqibo while
T933	activeingredient 40045 40074	VinCRIStine Sulfate Injection
T935	company 40075 40078	USP
T937	company 40081 40102	Hospira Australia Pty
T939	nanoparticle 40173 40191	Liposome Injection
T941	company 40193 40212	Cangene Corporation
T943	company 40214 40222	Winnipeg
T945	inactiveingredient 40252 40278	Sodium Phosphate Injection
T947	company 40280 40303	Jubilant HollisterStier
T949	company 40306 40313	Spokane
T951	tradename 40326 40337	Marqibo Kit
T953	activeingredient 40361 40389	vinCRIStine sulfate LIPOSOME
T955	nanoparticle 40390 40399	injection
T957	company 40401 40419	Anderson Packaging
T959	company 40421 40424	Inc
T961	company 40426 40434	Rockford
T963	company 40464 40482	Talon Therapeutics
T965	company 40484 40488	Inc.
T967	company 40490 40493	400
T969	tradename 40585 40594	Marqibo (
T971	activeingredient 40610 40638	vinCRIStine sulfate LIPOSOME
T973	nanoparticle 40639 40648	injection
T975	tradename 40710 40721	Marqibo and
T977	tradename 40734 40750	Marqibo infusion
T979	tradename 40911 40918	Marqibo
T981	tradename 40921 40931	Marqibo is
T983	indication 40982 41059	Philadelphia chromosome negative (Ph-) acutelymphoblastic leukemia (ALL) when
T985	tradename 41251 41261	Marqibo is
T987	tradename 41332 41340	Marqibo:
T989	tradename 41482 41492	Marqibo if
T991	activeingredient 41581 41603	vincristine sulfate or
T993	tradename 41630 41638	Marqibo.
T995	tradename 41698 41706	Marqibo.
T997	tradename 41759 41773	Marqibo causes
T999	routeofadministration 41816 41841	intravenous (IV) infusion
T1001	tradename 41892 41900	Marqibo?
T1003	tradename 41919 41926	Marqibo
T1005	activeingredient 41983 42005	vincristine sulfate in
T1007	adversereaction 42235 42247	constipation
T1009	tradename 42365 42376	Marqibo can
T1011	tradename 42446 42454	Marqibo.
T1013	tradename 42521 42529	Marqibo.
T1015	tradename 42597 42605	Marqibo.
T1017	tradename 42670 42684	Marqibo passes
T1019	tradename 42759 42769	Marqibo or
T1021	tradename 42948 42959	Marqibo may
T1023	tradename 43032 43045	Marqibo works
T1025	tradename 43182 43190	Marqibo?
T1027	tradename 43210 43220	Marqibo as
T1029	routeofadministration 43224 43249	intravenous (IV) infusion
T1031	tradename 43276 43286	Marqibo is
T1033	frequency 43301 43314	every 7 days.
T1035	tradename 43359 43371	Marqibo less
T1037	tradename 43407 43417	Marqibo if
T1039	tradename 43524 43532	Marqibo.
T1041	tradename 43572 43580	Marqibo?
T1043	tradename 43584 43595	Marqibo can
T1045	adversereaction 43613 43621	fatigue)
T1047	adversereaction 43642 43653	neuropathy)
T1049	tradename 43792 43800	Marqibo?
T1051	tradename 43858 43866	Marqibo?
T1053	tradename 43869 43880	Marqibo can
T1055	adversereaction 43922 43936	Tissue injury.
T1057	tradename 43939 43952	Marqibo leaks
T1059	adversereaction 44203 44214	neuropathy)
T1061	tradename 44248 44259	Marqibo and
T1063	tradename 44364 44374	Marqibo if
T1065	adversereaction 45131 45153	Low blood cell counts.
T1067	tradename 45157 45168	Marqibo may
T1069	adversereaction 45208 45215	anemia)
T1071	adversereaction 45240 45252	neutropenia)
T1073	adversereaction 45273 45290	thrombocytopenia)
T1075	tradename 45380 45388	Marqibo.
T1077	tradename 45435 45446	Marqibo and
T1079	adversereaction 45573 45607	Tumor lysis syndrome (TLS). TLS is
T1081	adversereaction 45651 45658	TLS can
T1083	tradename 45814 45821	Marqibo
T1085	adversereaction 45871 45916	Constipation and intestinal (bowel) blockage.
T1087	adversereaction 45985 46021	constipation or intestinal blockage.
T1089	adversereaction 46047 46074	stomach area (abdomen) pain
T1091	adversereaction 46076 46096	bloating or diarrhea
T1093	adversereaction 46098 46116	nausea or vomiting
T1095	adversereaction 46130 46138	fatigue)
T1097	tradename 46143 46154	Marqibo can
T1099	adversereaction 46287 46323	Liver problems that can cause death.
T1101	tradename 46326 46337	Marqibo can
T1103	adversereaction 46392 46428	liver problems that can cause death.
T1105	tradename 46505 46513	Marqibo.
T1107	tradename 46564 46574	Marqibo if
T1109	tradename 46629 46644	Marqibo include
T1111	adversereaction 46647 46653	nausea
T1113	adversereaction 46655 46660	fever
T1115	adversereaction 46662 46670	diarrhea
T1117	adversereaction 46672 46690	decreased appetite
T1119	adversereaction 46692 46706	sleep problems
T1121	tradename 46848 46856	Marqibo.
T1123	tradename 47053 47060	Marqibo
T1125	tradename 47249 47257	Marqibo.
T1127	tradename 47301 47308	Marqibo
T1129	tradename 47396 47408	Marqibo that
T1131	tradename 47548 47556	Marqibo?
T1133	activeingredient 47578 47597	vincristine sulfate
T1135	inactiveingredient 47622 47630	mannitol
T1137	corecomposition 47632 47645	sphingomyelin
T1139	corecomposition 47647 47658	cholesterol
T1141	inactiveingredient 47660 47674	sodium citrate
T1143	inactiveingredient 47677 47688	citric acid
T1145	inactiveingredient 47690 47727	sodium phosphate and sodium chloride.
T1147	company 47835 47853	Talon Therapeutics
T1149	company 47855 47859	Inc.
